WuXi AppTec IPO tops $353m
The Chinese contract research and development company WuXi AppTec has raised more than $353m in its initial public offering of common stock on the Shanghai Stock Exchange.
Archives for May 9, 2018
AstraZeneca offloads off-patent drug to focus on ‘main therapy areas’
In a deal worth up to $538m, AstraZeneca has entered into an agreement with Luye Pharma Group for the sale and license of the rights to Seroquel and Seroquel XR in several markets.
News in Brief
Suven passes US FDA inspection, secures CNS product patents
Suven Life Sciences has completed a US FDA renewal inspection at its Pashamylaram-based facility, which manufactures and supplies APIs, intermediates, and formulations.
RxCelerate buys biotech-focused accounting firm, names new CFO
The UK-based CRO RxCelerate continues to expand with its recent acquisition of The Cambridge Partnership for £1.45m ($1.96m) as it aims to carry out its vision of supporting virtual biotech companies.
Evotec, Carna Biosciences collaborate on INDiGO to treat blood cancer
Evotec has entered into a strategic collaboration to accelerate Carna Biosciences’s program CB-1763, which is being developed for the treatment of blood cancer.
Virtual clinical trials will be standard, says THREAD exec on Novartis project
Novartis’ recently launched FocalView app will be used in a new study to remotely collect electronic device reported outcome measurements (eDROs) from 150,000 users.
The Golden Ticket: Sanofi, Meditope initiate research collaboration to explore bioconjugation tech
Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.
Valeant, fleeing its toxic past, to rebrand as Bausch Health Companies
To distance itself from its troubled past, Valeant Pharmaceuticals is set to change its name to Bausch Health Companies, marking an important point in the "turnaround process," says CEO.